ENYO Pharma was present at the Europe Ambition Day in Lyon on October, 23rd 2018. This event, organized by the Auvergnes-Rhone-Alpes Entreprises, was opened to companies, academics and research centers in the region who wish to increase their chances of receiving funding from the European Commission. During the day, ENYO Pharma had the pleasure to participate to a panel discussion to share its success story and experience regarding the access to European fundings.
The ENYO team was present at the TechShare kick off meeting on Friday, September 21th, 2018. TechShare is a unique pan-European programme organized by Euronext to boost the funding of innovative companies by financial markets. On this occasion, Euronext has welcomed the 135 non listed most promising European start-ups in order to develop the minimum skills to be listed on stock market. This programme, organized for the 4th consecutive year, has allowed ENYO Pharma to understand the benefits and disadvantages to choose this type of financing to support the company’s growth.
The 26th edition of the Entrepreneur of the year Auvergne-Rhone-Alpes took place on September 17th, 2018 in Lyon. The “Start-Up of the Year” Award has been granted to Jacky Vonderscher, CEO of ENYO Pharma. This Award recognizes the company both for its high innovation on the biotech market and its high growth leading ENYO Pharma to become one of the leaders of tomorrow. Thus, the company reached the next step of the “Entrepreneur of the year” Award which will take place at national level on October 18th 2018 in Paris!
ENYO Pharma was present at the EIC Innovators’ Summit in Berlin on September, 10th-11th 2018, organized by the European Innovation Council. We had the pleasure to make presentations at several workshops during this summit. The workshops allowed participants to be creative and to strengthen their knowledge thanks to several experience sharings of our team members. On this occasion, it was a great opportunity for ENYO Pharma to have fruitful meetings and conversations,
ENYO Pharma is pleased to collaborate with Novadiscovery and Calvagone which will present the first in silico liver disease model and the pharmackinetics-pharmacodynamics analysis respectivelly of EYP001 treatment effect on Hepatitis B virus (HBV) infected patients at the PAGE Meeting, May 29th – June 1st, 2018 in Switzerland.